Does astrocyte pyroptosis help explain stress depression in mice?
In a mouse chronic-mild-stress model, hippocampal astrocytes died by NLRP3/caspase-1/GSDMD pyroptosis; knocking out that cascade (or giving an SSRI) eased depression-like behavior, while putting GSDMD-N back in astrocytes wiped out the benefit.
Source
NLRP3/caspase-1/GSDMD-mediated pyroptosis exerts a crucial role in astrocyte pathological injury in mouse model of depression
Study at a glance
- Design
- Animal / in-vitro — Mouse chronic mild stress (CMS) plus astrocyte-targeted NLRP3/Casp-1/GSDMD genetics and SSRI treatment; hippocampal pyroptosis and depression-like behavior
- N
- N=8 · Typical behavioral cohorts n = 8 mice/group; immunoblots n = 4/group; mixed WT, NLRP3-cKO, Casp-1−/−, GSDMD−/− lines
- Population
- Male C57BL/6J mice (WT, astrocytic NLRP3-cKO, Casp-1 and GSDMD knockouts) under CMS
- Outcome
- Depression-like behavior (SPT/FST) and astrocytic NLRP3/Casp-1/GSDMD pyroptosis in hippocampus
Structured fields used in claim comparison tables when every cited study has a complete layer.
Inspect source passages
Does astrocyte pyroptosis help explain stress depression in mice?
These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.
Behavioral assays often used n = 8 mice/group.
n = 8 mice per group
Sucrose preference fell by the end of week 6 of CMS.
CMS mice manifested a significant reduction in sucrose consumption compared with that in the control group observed at the end of week 6
What they did
Exposed male C57BL/6J mice to CMS for up to 6 weeks (SPT/FST), measured hippocampal Casp-1/GSDMD/IL-1β and astrocytic pyroptosis, then used GSDMD, Casp-1, and astrocytic NLRP3 knockouts plus SSRI (fluoxetine/citalopram) and astrocytic GSDMD-N overexpression.
What they found
CMS cut sucrose preference by week 6 and raised FST immobility. Depressive mice showed astrocytic pyroptosis and astrocyte loss; SSRIs reduced that pyroptosis. Genetic KO of GSDMD, Casp-1, or astrocytic NLRP3 improved behavior and lowered pyroptosis proteins; hippocampal GSDMD-N overexpression reversed GSDMD-KO benefits.
The limits
What it doesn't show
Mouse CMS is not human MDD; targeting NLRP3/GSDMD is a mechanistic hypothesis, not a licensed antidepressant strategy, and n is small per group.
Key terms
- Pyroptosis
- Inflammatory programmed cell death driven by caspase cleavage of gasdermin D.
- NLRP3 inflammasome
- Cytosolic sensor complex that activates caspase-1; here targeted in astrocytes.
- GSDMD-N
- N-terminal fragment of gasdermin D that forms membrane pores.
- CMS
- Chronic mild stress used to induce depression-like behavior.
- SPT / FST
- Sucrose preference (anhedonia) and forced-swim (immobility) tests.
- SSRI
- Fluoxetine and citalopram; here they also reduced CMS-induced pyroptosis.
Flashcards
0 of 10 answers reviewed
Research intelligence for this paper
See its role on concept claims, tensions it is part of, placement history, and related discoveries.
Quiz yourself
The pyroptotic cells were mainly:
Common questions
Which cell type pyroptosed?
Astrocytes in hippocampus, via NLRP3/Casp-1/GSDMD.
Did SSRIs affect pyroptosis?
Yes—SSRI treatment attenuated CMS-induced pyroptosis.
What reversed GSDMD-KO rescue?
Overexpressing astrocytic GSDMD-N in hippocampus.
Typical n per behavior group?
n = 8 mice per group.
More on Depression